Homeグループ紹介 > 分子治療グループ

グループ紹介

分子治療グループ

主な論文

  1. Makino H, Aoki M, Hashiya N, Yamasaki K, Azuma J, Sawa Y, Kaneda Y, Ogihara T, and Morishita R. Long Term Follow Up Evaluation of Results From Clinical Trial (TREAT-HGF) Using Hepatocyte Growth Factor Gene to Treat Severe Peripheral Arterial Disease. ATVB 2012 in press
  2. Morishita R, Makino H, Aoki M, Hashiya N, Yamasaki K, Azuma J, Taniyama Y, Sawa Y, Kaneda Y, Ogihara T. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol. 2011 Mar;31(3):713-20. Epub 2010 Dec 23.
  3. Hanayama R, Shimizu H, Nakagami H, Osako MK, Makino H, Kunugiza Y, Tomita T, Tsukamoto I, Yoshikawa H, Rakugi H, Morishita R. Fluvastatin improves osteoporosis in fructose-fed insulin resistant model rats through blockade of the classical mevalonate pathway and antioxidant action. Int J Mol Med. 2009 May;23(5):581-8.
  4. Fujiwara Y, Shiraya S, Miyake T, Yamakawa S, Aoki M, Makino H, Nishimura M, Morishita R. Inhibition of experimental abdominal aortic aneurysm in a rat model by the angiotensin receptor blocker valsartan. Int J Mol Med. 2008 Dec;22(6):703-8.
  5. Takeya Y, Makino H, Aoki M, Miyake T, Ozaki K, Rakugi H, Ogihara T, Morishita R. In Vivo Evidence of Enhancement of HGF-induced Angiogenesis by Fluvastatin. The Open Gene Therapy 2008;1(1): 1-6
  6. Nakagawa A, Makino H, Aoki M, Miyake T, Shiraya S, Nakamura T, Ogihara T, Kimata Y, Morishita R. Improvement of survival of skin flaps by combined gene transfer of hepatocyte growth factor and prostacyclin synthase. J Gene Med. 2007 Dec;9(12):1087-94.
  7. Makino H, Aoki M, Hashiya N, Yamasaki K, Shimizu H, Miwa K, Ogihara T, Morishita R. A calcium-channel blocker, benidipine, improves forearm reactive hyperemia in patients with essential hypertension. Blood Press Suppl. 2005 Jul;1:39-44.
  8. Tashiro H, Aoki M, Isobe M, Hashiya N, Makino H, Kaneda Y, Ogihara T, Morishita R. Development of novel method of non-viral efficient gene transfer into neonatal cardiac myocytes. J Mol Cell Cardiol. 2005 Sep;39(3):503-9.
  9. Morishita R, Aoki M, Hashiya N, Makino H, Yamasaki K, Azuma J, Sawa Y, Matsuda H, Kaneda Y, Ogihara T. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension. 2004 Aug;44(2):203-9.
  10. Yamasaki K, Aoki M, Makino H, Hashiya N, Shimizu H, Ohishi M, Ogihara T, Morishita R. Effect of nifedipine on endothelial function in normotensive smokers: potential contribution of increase in circulating hepatocyte growth factor. J Hum Hypertens. 2004 Oct;18(10):701-5.
  11. Hashiya N, Aoki M, Tachibana K, Taniyama Y, Yamasaki K, Hiraoka K, Makino H, Yasufumi K, Ogihara T, Morishita R. Local delivery of E2F decoy oligodeoxynucleotides using ultrasound with microbubble agent (Optison) inhibits intimal hyperplasia after balloon injury in rat carotid artery model. Biochem Biophys Res Commun. 2004 Apr 30;317(2):508-14.
  12. Morishita R, Aoki M, Hashiya N, Yamasaki K, Kurinami H, Shimizu S, Makino H, Takeya Y, Azuma J, Ogihara T. Therapeutic angiogenesis using hepatocyte growth factor (HGF). Curr Gene Ther. 2004 Jun;4(2):199-206. Review.
  13. Makino H, Aoki M, Hashiya N, Yamasaki K, Hiraoka K, Shimizu H, Azuma J, Kurinami H, Ogihara T, Morishita R. Increase in peripheral blood flow by intravenous administration of prostaglandin E1 in patients with peripheral arterial disease, accompanied by up-regulation of hepatocyte growth factor. Hypertens Res. 2004 Feb;27(2):85-91.
  14. Namba T, Koike H, Murakami K, Aoki M, Makino H, Hashiya N, Ogihara T, Kaneda Y, Kohno M, Morishita R. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation. 2003 Nov 4;108(18):2250-7.
  15. Yamasaki K, Asai T, Shimizu M, Aoki M, Hashiya N, Sakonjo H, Makino H, Kaneda Y, Ogihara T, Morishita R. Inhibition of NFkappaB activation using cis-element 'decoy' of NFkappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther. 2003 Feb;10(4):356-64.
[分子治療グループ]
Page Top